Story perspectives

Pfizer Beats Q4 Estimates, Faces Cautious Future

2/4/2026

Summary

Story summary

Pfizer Inc. reported fourth-quarter results that beat estimates, with adjusted earnings per share of $0.66 and revenue of $17.56 billion.
Pfizer faces declining demand for Covid products and upcoming patent expirations.
For 2026, Pfizer expects earnings per share of $2.80 to $3.00, below some analysts.
The company is investing in its pipeline, including a $10 billion Metsera acquisition with promising mid-stage results.
Shares fell as the cautious outlook persisted.

History

Historical Context

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 transformed the U.S. pharmaceutical landscape, significantly boosting drug sales. By Q4 2022, Pfizer reported $17.56 billion in revenue, facing challenges from declining Covid product demand and patent expirations. Historically, pharmaceutical companies have struggled with revenue loss post-patent expiration, necessitating innovation and strategic acquisitions like Pfizer's $10 billion purchase of Metsera to maintain growth.

1 of 2

Story summary

Pfizer Inc. reported fourth-quarter results that beat estimates, with adjusted earnings per share of $0.66 and revenue of $17.56 billion.
Pfizer faces declining demand for Covid products and upcoming patent expirations.
For 2026, Pfizer expects earnings per share of $2.80 to $3.00, below some analysts.
The company is investing in its pipeline, including a $10 billion Metsera acquisition with promising mid-stage results.
Shares fell as the cautious outlook persisted.

1 / 2